Chinese biotech groups are on target to raise about $10bn this year from venture capital funding, initial public offerings and licensing deals with overseas pharma companies, in what is partly a bet that Chinese-developed drugs can compete globally.
An estimated 300 million Chinese people are smokers. China has also a serious issue with hazardous air pollution. Here concentrations of small, breathable particles (PM2.5) invariably exceeding 300 micrograms per cubic meter in the industrialized northern regions.
Since October 2016, China has seen a “fifth wave” of H7N9 infections. Nearly 1,600 people have tested positive, almost 40 percent of whom have died.
As the world’s largest generics maker, Teva still doesn’t have much of a presence in China, even though it is a country relies heavily on generics. The Israeli company is looking to remedy that by reportedly forming a joint venture with local company Guangzhou Pharma
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.